[1]
Haznedaroglu, I. 2013. MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML). Mediterranean Journal of Hematology and Infectious Diseases. 6, 1 (Dec. 2013), e2014009. DOI:https://doi.org/10.4084/mjhid.2014.009.